The interleukin 23 inhibitor was approved for treating moderate-to-severe plaque psoriasis in adults in 2019 and for active psoriatic arthritis in adults in 2022.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/fda-extends-risankizumab-approval-children-psoriasis-2026a1000m0a?src=rss
Author :
Publish date : 2026-06-29 12:30:00
Copyright for syndicated content belongs to the linked Source.
